Pulmatrix (NASDAQ:PULM) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Pulmatrix (NASDAQ:PULM) in a research report report published on Tuesday. The firm issued a hold rating on the biotechnology company’s stock.

Pulmatrix Price Performance

NASDAQ:PULM opened at $1.95 on Tuesday. The firm has a market capitalization of $7.12 million, a price-to-earnings ratio of -0.51 and a beta of 0.92. The company’s 50-day moving average is $1.84 and its two-hundred day moving average is $1.88. Pulmatrix has a 1-year low of $1.55 and a 1-year high of $3.14.

Pulmatrix (NASDAQ:PULM) last posted its earnings results on Thursday, March 28th. The biotechnology company reported ($0.57) earnings per share for the quarter. The firm had revenue of $2.20 million during the quarter. Pulmatrix had a negative net margin of 193.49% and a negative return on equity of 63.94%.

Institutional Investors Weigh In On Pulmatrix

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. raised its stake in shares of Pulmatrix by 62.9% in the 4th quarter. Vanguard Group Inc. now owns 35,082 shares of the biotechnology company’s stock valued at $65,000 after acquiring an additional 13,548 shares during the period. Susquehanna International Group LLP purchased a new stake in shares of Pulmatrix in the 1st quarter valued at approximately $73,000. Mariner LLC purchased a new stake in shares of Pulmatrix in the 4th quarter valued at approximately $97,000. Citadel Advisors LLC purchased a new stake in shares of Pulmatrix in the 2nd quarter valued at approximately $141,000. Finally, Renaissance Technologies LLC raised its stake in shares of Pulmatrix by 7.3% in the 2nd quarter. Renaissance Technologies LLC now owns 121,920 shares of the biotechnology company’s stock valued at $560,000 after acquiring an additional 8,300 shares during the period. 11.84% of the stock is owned by hedge funds and other institutional investors.

Pulmatrix Company Profile

Pulmatrix, Inc, a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.